Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Mehta Discusses the Reliability of Automated Segmentation for Lung Volumes in Multiple Cancers

September 23rd 2014

Niraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.

Multiple Factors Impact BRCA Testing Decision

September 23rd 2014

More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.

Most Breast Cancer Patients Forgo Reconstruction Surgery Without Regret

September 22nd 2014

Although universal insurance coverage for postmastectomy breast reconstruction has been mandated since 1998, a new study has found that the persistently high rates of American women who choose not to undergo reconstruction surgery are due primarily to patient preferences and not a lack of awareness.

Dr. Attai Discusses 5-Year Outcomes for APBI With Strut-Based Brachytherapy

September 17th 2014

Deanna J. Attai, MD, discusses a 5-year follow up of patients receiving accelerated partial breast irradiation (APBI) using strut-based applicators.

Pertuzumab Use Continues to Expand in Breast Cancer

September 17th 2014

Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.

CDK 4/6, PI3K Inhibitor Combinations Explored in Breast Cancer

September 11th 2014

The combination of letrozole with either the CDK4/6 inhibitor LEE011 or the PI3 kinase Inhibitor BYL719 demonstrated clinical activity for women with ER-positive, HER2-negative breast cancer.

Oncologist Data from a New Survey Addresses the Emotional Impact of Treating Advanced Breast Cancer

September 10th 2014

Data from a brand new survey addressed some of the emotional issues faced by physicians when treating and delivering a diagnosis of advanced breast cancer.

Hurvitz Discusses PIK3CA Mutations, pCR, CDK4/6 Inhibitors, and Immunotherapies in Breast Cancer

September 9th 2014

Sara Hurvitz, MD, highlights key points on the PIK3CA mutation, and addresses several other key topics in the field of breast cancer.

Dr. Gralow on the Use of Bisphosphonates in Early-Stage Breast Cancer

September 9th 2014

Julie R. Gralow, MD, discusses the use of bisphosphonates in early-stage breast cancer.

Dr. Chan on Improving Mammography Screening Rates With Signed Letters

September 8th 2014

Elisa K. Chan, MD, discusses improving mammography screening rates with signed letters from physicians. Chan worked for the BC Cancer Agency during the study.

Adding Trastuzumab to Fulvestrant Prolongs Responses in Metastatic Breast Cancer

September 7th 2014

The addition of trastuzumab to fulvestrant prolonged responses compared with fulvestrant alone for certain patients with metastatic breast cancer.

Novel Peptide Vaccine Safe, Effective in High-Risk Breast Cancer

September 6th 2014

A novel HER2-derived peptide vaccine designed to stimulate CD8+ cytotoxic T-lymphocytes reduced the rate of breast cancer recurrence and proved safe and well tolerated in the adjuvant setting.

Veliparib Active in Patients with BRCA-Positive Breast, Ovarian Tumors

September 6th 2014

The PARP inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.

Fertility May Be Preserved With Triptorelin Adjuvant to Chemotherapy in Younger Breast Cancer Patients

September 5th 2014

Long-term follow-up of a phase III clinical trial shows strong trends toward a greater likelihood of resuming menses and becoming pregnant when a luteinizing hormone-releasing hormone (LH-RH) analog is administered with chemotherapy in patients with breast cancer

In Early Breast Cancer, Outcomes Affected by Tumor Biology and Choice of Local Treatment

September 5th 2014

Breast conserving therapy (BCT) improves overall survival compared with other local treatments in patients with stage I breast cancer, according to an examination of the National Cancer Database (NCDB).

Dr. Sisco Discusses Complications After Bilateral and Unilateral Mastectomies with Immediate Reconstruction

September 5th 2014

Mark Sisco, MD, Clinical Assistant Professor, Division of Plastic and Reconstructive Surgery, NorthShore Univeristy HealthSystem, discusses the results of a NSQIP analysis of 30-day complications after bilateral versus unilateral mastectomy with immediate reconstruction

Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast Cancer

September 5th 2014

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.

Targeting the Androgen Receptor: New Hope for Aggressive Forms of Prostate and Breast Cancer

September 5th 2014

Although hormone-targeting strategies have been a mainstay of prostate and breast cancer therapies for decades, an improved understanding of the mechanisms underlying these malignancies has led researchers to focus fresh attention on the complex activity of the androgen receptor (AR) as a point of attack.

ASCO Issues New Guideline for Advanced HER2-Negative Breast Cancer

September 3rd 2014

The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.

Dr. Tripathy Provides an Overview of the SystHERs Registry

September 2nd 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, provides an overview of the SystHERs registry.